

Statement from ProQinase's CEO, Dr. Sebastian Dempe

In brief:

- All divisions of ProQinase and Reaction Biology are fully operational
- Contingency plan in place,
- Adherence to governmental advice on social distancing

Dear Partner,

The spread of Sars-Cov2 virus has now reached all most regions of Europe and the US. In order to fulfill our social responsibility and to adhere to local government recommendations to help to decelerate virus transmission rate as well as to provide maximum protection to our workers, we have set various measurements in place, incl. provision of flexible working conditions and arrangements, establishment of single person's offices, single lab space environments for most of our technicians, as well as increased safety protections for members of our animal facility. A contingency plan is in full execution enabling us to flexibly respond to increased workloads seen in the various divisions of our operations.

As we have recently increased our inventories for routine consumables, we currently do not foresee any delays due to disruption of supply chains. While the situation remains dynamic, we promise to stay in very close contact to you as our partner to increase communication levels with you even further.

I want to assure you that our commitment is unbroken to continuously provide high quality and timely support of your subcontracted preclinical activities in drug discovery for the foreseeable future.

Cordially,

Sebastian



Dr. Sebastian Dempe
CEO, Managing Director
ProQinase + Reaction Biology
Engesserstrasse 4
79108 Freiburg, Germany

Sebastian Dempe, PhD
CEO/ Managing Director

ProQinase GmbH
Engesserstr. 4
79108 Freiburg
Germany

E-mail: s.dempe@proqinase.com

Phone: +49-761-769 996 1700

Mobile: +49-176-80 77 61 34

Web: www.proqinase.com